BSA-embedded carbonate apatite enhances chemotherapeutic effect of paclitaxel in vitro and in vivo

Introduction of biocompatible ingredients into nano-material formulations has been studied as a strategy for the enhancement of the pharmacokinetics as well as pharmacodynamics of the final product. With the aim of enhancing drug loading and the ultimate efficacy, incorporation of Bovine Serum Albumin (BSA) into carbonate apatite (CA) nanoparticles structure was employed in the present study. As a result of BSA embedding in the CA formulation, approximately three-times higher loading efficiency was achieved for paclitaxel (Pac). Moreover, BSA-embedded CA complexed with paclitaxel conferred increased efficacy in limiting the viability of cancer cells compared to CA/Pac, and this effect was recorded in breast cancer cell culture as well as in the animal model. Taken together, with favorable drug binding and suitable in vivo efficacy, BSA-incorporated carbonate apatite may be engineered into a high potency nano-carrier with extensive application in the upcoming research.